Skip to content
SC Pembro, Biotin, 5-yr POLARIX data episode artwork

Sep 25, 2025 18 min

SC Pembro, Biotin, 5-yr POLARIX data

from OncoPharm Hosted by John Bossaer

The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use. Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://doi.org/10.1200/OP-25-00693 POLARIX 5-year Data: https://doi.org/10.1200/JCO-25-00925

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

SC Pembro, Biotin, 5-yr POLARIX data

0:00 18:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 18 minutes long.

When was this OncoPharm episode published?

This episode was published on September 25, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.